Declared Dividend • May 25
Dividend of CN¥0.40 announced Shareholders will receive a dividend of CN¥0.40. Ex-date: 28th May 2026 Payment date: 28th May 2026 Dividend yield will be 3.5%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (49% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 38% per year over the past 8 years. However, payments have been volatile during that time. Earnings per share has grown by 25% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 25
First quarter 2026 earnings released: EPS: CN¥0.11 (vs CN¥0.25 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.11 (down from CN¥0.25 in 1Q 2025). Revenue: CN¥595.2m (down 14% from 1Q 2025). Net income: CN¥56.7m (down 55% from 1Q 2025). Profit margin: 9.5% (down from 18% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Tillkännagivande • Apr 25
Hunan Jiudian Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2026 Hunan Jiudian Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Changsha, Hunan China Tillkännagivande • Mar 31
Hunan Jiudian Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Apr 25, 2026 Hunan Jiudian Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026 Tillkännagivande • Dec 31
Hunan Jiudian Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Apr 25, 2026 Hunan Jiudian Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Apr 25, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.23 (vs CN¥0.34 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.23 (down from CN¥0.34 in 3Q 2024). Revenue: CN¥756.1m (down 3.0% from 3Q 2024). Net income: CN¥114.9m (down 31% from 3Q 2024). Profit margin: 15% (down from 21% in 3Q 2024). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Tillkännagivande • Sep 30
Hunan Jiudian Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Hunan Jiudian Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Reported Earnings • Aug 25
Second quarter 2025 earnings released: EPS: CN¥0.34 (vs CN¥0.33 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.34 (up from CN¥0.33 in 2Q 2024). Revenue: CN¥815.9m (up 5.2% from 2Q 2024). Net income: CN¥165.6m (up 4.5% from 2Q 2024). Profit margin: 20% (in line with 2Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Jul 16
Now 20% overvalued The stock has been flat over the last 90 days, currently trading at CN¥16.54. The fair value is estimated to be CN¥13.77, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 29%. Revenue is forecast to grow by 33% in 2 years. Earnings are forecast to grow by 37% in the next 2 years. Tillkännagivande • Jul 02
Hunan Jiudian Pharmaceutical Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025 Hunan Jiudian Pharmaceutical Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025 Buy Or Sell Opportunity • Jun 10
Now 21% overvalued The stock has been flat over the last 90 days, currently trading at CN¥16.86. The fair value is estimated to be CN¥13.88, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 29%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 54% in the next 2 years. Declared Dividend • May 23
Dividend of CN¥0.31 announced Shareholders will receive a dividend of CN¥0.31. Ex-date: 26th May 2025 Payment date: 26th May 2025 Dividend yield will be 2.0%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (30% earnings payout ratio) and cash flows (55% cash payout ratio). The dividend has increased by an average of 39% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 33% over the next year, which should provide support to the dividend and adequate earnings cover. Tillkännagivande • Apr 25
Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2024 Hunan Jiudian Pharmaceutical Co., Ltd. announced on 24 April 2025 the profit distribution proposal for the year 2024 as final cash dividend/10 shares (tax included) of CNY 3.10000000. Reported Earnings • Apr 24
First quarter 2025 earnings released: EPS: CN¥0.25 (vs CN¥0.26 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.25. Revenue: CN¥696.0m (up 18% from 1Q 2024). Net income: CN¥125.8m (flat on 1Q 2024). Profit margin: 18% (down from 21% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Tillkännagivande • Apr 24
Hunan Jiudian Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2025 Hunan Jiudian Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Changsha, Hunan China Tillkännagivande • Mar 31
Hunan Jiudian Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Apr 24, 2025 Hunan Jiudian Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Apr 24, 2025 Tillkännagivande • Feb 19
Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) announces an Equity Buyback for CNY 150 million worth of its shares. Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) announces a share repurchase program. Under the program, the company will repurchase up to CNY 150 million worth of its A shares. The shares will be purchased at a price not exceeding CNY 24.98 per share. The repurchases will be funded from special loan funds for stock repurchase. The repurchased shares will be used for for implementing the equity incentive plan. The program will be valid for 12 months. Price Target Changed • Jan 23
Price target decreased by 15% to CN¥29.00 Down from CN¥34.10, the current price target is provided by 1 analyst. New target price is 88% above last closing price of CN¥15.46. Stock is down 31% over the past year. The company is forecast to post earnings per share of CN¥1.08 for next year compared to CN¥0.76 last year. Tillkännagivande • Dec 31
Hunan Jiudian Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Apr 24, 2025 Hunan Jiudian Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on Apr 24, 2025 Valuation Update With 7 Day Price Move • Dec 31
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to CN¥17.95, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 6.6% over the past three years. New Risk • Nov 18
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (2.3% increase in shares outstanding). Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.23 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.34 (up from CN¥0.23 in 3Q 2023). Revenue: CN¥779.7m (up 16% from 3Q 2023). Net income: CN¥165.6m (up 47% from 3Q 2023). Profit margin: 21% (up from 17% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 29% per year. Valuation Update With 7 Day Price Move • Oct 02
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to CN¥24.63, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 95% over the past three years. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.3% average weekly change). Tillkännagivande • Sep 30
Hunan Jiudian Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024 Hunan Jiudian Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024 Reported Earnings • Aug 24
Second quarter 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.26 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.33 (up from CN¥0.26 in 2Q 2023). Revenue: CN¥775.3m (up 8.3% from 2Q 2023). Net income: CN¥158.5m (up 31% from 2Q 2023). Profit margin: 20% (up from 17% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥22.85, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 72% over the past three years. Tillkännagivande • Jun 29
Hunan Jiudian Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024 Hunan Jiudian Pharmaceutical Co., Ltd. announced that they will report first half, 2024 results on Aug 24, 2024 Valuation Update With 7 Day Price Move • May 23
Investor sentiment deteriorates as stock falls 31% After last week's 31% share price decline to CN¥25.44, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 20% over the past three years. Declared Dividend • May 20
Dividend increased to CN¥0.32 Dividend of CN¥0.32 is 36% higher than last year. Ex-date: 24th May 2024 Payment date: 24th May 2024 Dividend yield will be 0.9%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (26% earnings payout ratio) and cash flows (58% cash payout ratio). The dividend has increased by an average of 40% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 95% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Tillkännagivande • Apr 27
Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023 Hunan Jiudian Pharmaceutical Co., Ltd. proposed final cash dividend per 10 shares (tax included) of CNY 3.21000000 for the year 2023. Tillkännagivande • Apr 26
Hunan Jiudian Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2024 Hunan Jiudian Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Changsha, Hunan China Reported Earnings • Apr 25
First quarter 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.22 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.36 (up from CN¥0.22 in 1Q 2023). Revenue: CN¥590.9m (up 18% from 1Q 2023). Net income: CN¥125.7m (up 63% from 1Q 2023). Profit margin: 21% (up from 15% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Mar 30
Hunan Jiudian Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024 Hunan Jiudian Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024 Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥33.88, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total returns to shareholders of 98% over the past three years. Tillkännagivande • Jan 27
Hunan Jiudian Pharmaceutical Co., Ltd. Elects Yang Yang and Fan Pengyun as Non-Independent Director Hunan Jiudian Pharmaceutical Co., Ltd. at the Extraordinary General Meeting of 2024 on 25 January 2024 approved election and nomination of non-independent directors, cumulative voting system applicable: Yang Yang, non-independent director; Fan Pengyun, non-independent director. Tillkännagivande • Dec 29
Hunan Jiudian Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024 Hunan Jiudian Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results on Apr 25, 2024 Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥32.90, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 99% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥65.33 per share. Reported Earnings • Oct 24
Third quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.24 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.32 (up from CN¥0.24 in 3Q 2022). Revenue: CN¥675.2m (up 19% from 3Q 2022). Net income: CN¥112.4m (up 43% from 3Q 2022). Profit margin: 17% (up from 14% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Sep 30
Hunan Jiudian Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023 Hunan Jiudian Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Oct 24, 2023 Reported Earnings • Aug 16
Second quarter 2023 earnings released: EPS: CN¥0.36 (vs CN¥0.22 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.36 (up from CN¥0.22 in 2Q 2022). Revenue: CN¥715.8m (up 23% from 2Q 2022). Net income: CN¥120.7m (up 64% from 2Q 2022). Profit margin: 17% (up from 13% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 04
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥21.42, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 54% over the past three years. Tillkännagivande • Jul 01
Hunan Jiudian Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 16, 2023 Hunan Jiudian Pharmaceutical Co., Ltd. announced that they will report first half, 2023 results on Aug 16, 2023 Tillkännagivande • May 10
Hunan Jiudian Pharmaceutical Co., Ltd. Approves 2022 Final Profit Distribution, Payable on May 15, 2023 Hunan Jiudian Pharmaceutical Co., Ltd. approved 2022 final profit distribution plan to be implemented (A shares), payable on May 15, 2023. The company approved Cash dividend/10 shares (tax included) of CNY 2.36000000. Record date: May 12, 2023. Ex-date: May 15, 2023.Payment date is 15 May 2023. Reported Earnings • Apr 16
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: CN¥0.82 (up from CN¥0.62 in FY 2021). Revenue: CN¥2.33b (up 43% from FY 2021). Net income: CN¥269.7m (up 32% from FY 2021). Profit margin: 12% (in line with FY 2021). Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) also surpassed analyst estimates by 1.7%. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment deteriorated over the past week After last week's 20% share price decline to CN¥21.71, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 158% over the past three years. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). GM & Director Xia Hui Zheng was the last director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.17 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.24 (up from CN¥0.17 in 3Q 2021). Revenue: CN¥568.2m (up 43% from 3Q 2021). Net income: CN¥78.6m (up 39% from 3Q 2021). Profit margin: 14% (in line with 3Q 2021). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 54% per year whereas the company’s share price has increased by 53% per year. Valuation Update With 7 Day Price Move • Oct 14
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥23.91, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 201% over the past three years. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥20.61, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 152% over the past three years. Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥19.01, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 123% over the past three years. Reported Earnings • Jul 31
Second quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.20 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.22 (up from CN¥0.20 in 2Q 2021). Revenue: CN¥581.9m (up 28% from 2Q 2021). Net income: CN¥73.8m (up 11% from 2Q 2021). Profit margin: 13% (down from 15% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 41%, compared to a 23% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth. Tillkännagivande • May 21
Hunan Jiudian Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 27 May 2022 Hunan Jiudian Pharmaceutical Co., Ltd. announced cash dividend/10 shares (tax included) of CNY 2.61000000 for A shares for the year 2021. Record date is 26 May 2022. Ex-date is 27 May 2022. Payment date is 27 May 2022. Tillkännagivande • May 19
Hunan Jiudian Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021 Hunan Jiudian Pharmaceutical Co., Ltd. at the AGM held on May 17, 2022, approved Cash dividend per 10 shares (tax included) of CNY 2.61000000 for 2021. Valuation Update With 7 Day Price Move • May 10
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥23.84, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 102% over the past three years. Tillkännagivande • Apr 28
Nan Jiudian Pharmaceutical Announces Profit Distribution Plan for 2021 Hunan Jiudian Pharmaceutical Co., Ltd. proposed cash dividend/10 shares (tax included) of CNY 2.61000000 for the year 2021. Reported Earnings • Apr 27
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: EPS: CN¥0.24 (up from CN¥0.20 in 1Q 2021). Revenue: CN¥449.1m (up 62% from 1Q 2021). Net income: CN¥56.0m (up 21% from 1Q 2021). Profit margin: 13% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 40%, compared to a 26% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Sheng He Tang was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Mar 08
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥23.93, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 25x in the Pharmaceuticals industry in China. Total returns to shareholders of 64% over the past three years. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥29.55, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 143% over the past three years. Valuation Update With 7 Day Price Move • Dec 14
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥30.75, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 156% over the past three years. Valuation Update With 7 Day Price Move • Nov 23
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥28.13, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 121% over the past three years. Reported Earnings • Oct 26
Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.097 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥397.9m (up 51% from 3Q 2020). Net income: CN¥56.4m (up 152% from 3Q 2020). Profit margin: 14% (up from 8.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥23.58, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 46% over the past three years. Tillkännagivande • Aug 12
Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) entered into an agreement to acquire Hunan Huiyang Information Technology Co., Ltd. from Duan Lixin and Duan Linong for CNY 8.56 million. Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) entered into an agreement to acquire Hunan Huiyang Information Technology Co., Ltd. from Duan Lixin and Duan Linong for CNY 8.56 million on August 9, 2021. Duan Lixin will transfer 95% stake and Duan Linong will transfer 5% stake of Hunan Huiyang Information Technology. Pursuant to the agreement, Jiudian Pharmaceutical shall pay the seller a one-off cash consideration within 15 working days from the date of completion. The board of directors of Hunan Jiudian Pharmaceutical approved the transaction. Reported Earnings • Aug 10
Second quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.11 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥453.6m (up 95% from 2Q 2020). Net income: CN¥66.4m (up 158% from 2Q 2020). Profit margin: 15% (up from 11% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 19
Investor sentiment deteriorated over the past week After last week's 20% share price decline to CN¥35.09, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 60% over the past three years. Valuation Update With 7 Day Price Move • Jun 09
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥33.79, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 28x in the Pharmaceuticals industry in China. Total returns to shareholders of 36% over the past three years. Reported Earnings • Apr 18
Full year 2020 earnings released: EPS CN¥0.35 (vs CN¥0.23 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥978.2m (up 5.9% from FY 2019). Net income: CN¥82.3m (up 49% from FY 2019). Profit margin: 8.4% (up from 6.0% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Tillkännagivande • Mar 08
Hunan Jiudian Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 17, 2021 Hunan Jiudian Pharmaceutical Co., Ltd. announced that they will report fiscal year 2020 results on Apr 17, 2021 Reported Earnings • Mar 04
Full year 2020 earnings released: EPS CN¥0.34 (vs CN¥0.23 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥978.1m (up 5.9% from FY 2019). Net income: CN¥80.3m (up 46% from FY 2019). Profit margin: 8.2% (up from 6.0% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Jan 22
New 90-day high: CN¥28.81 The company is up 33% from its price of CN¥21.70 on 23 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period. Is New 90 Day High Low • Dec 11
New 90-day high: CN¥25.00 The company is up 13% from its price of CN¥22.10 on 11 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥72.4m, up 11% from the prior year. Total revenue was CN¥921.4m over the last 12 months, up 2.4% from the prior year. Tillkännagivande • Aug 01
Hunan Jiudian Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 22, 2020 Hunan Jiudian Pharmaceutical Co., Ltd. announced that they will report first half, 2020 results on Aug 22, 2020